Comparative Pharmacology
Head-to-head clinical analysis: CYCRIN versus MEGACE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCRIN versus MEGACE.
CYCRIN vs MEGACE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Medroxyprogesterone acetate is a progestin that inhibits gonadotropin secretion, suppressing ovulation and inducing a withdrawal bleeding in an estrogen-primed endometrium. It exerts its effects via binding to progesterone receptors, leading to endometrial transformation and inhibition of endometrial proliferation.
Megestrol acetate is a synthetic progestin that inhibits pituitary gonadotropin secretion, leading to suppression of ovarian function and reduction of sex hormone levels. It also has antineoplastic effects through interference with estrogen receptor binding and may stimulate appetite via effects on neuropeptide Y and cytokines.
2.5 mg to 10 mg orally once daily for 5 to 10 days per cycle.
Oral: 625 mg (suspension) or 400–800 mg (tablets) once daily.
None Documented
None Documented
Terminal elimination half-life ranges from 12 to 24 hours, supporting once-daily dosing for continuous hormone replacement.
Terminal elimination half-life: 70-95 hours (mean 85 hours) in chronic dosing; shorter in initial doses; clinical context: requires 3-4 weeks to reach steady state.
Primarily renal (50-60% as sulfate and glucuronide conjugates), with approximately 30% fecal elimination.
Primarily renal: ~75% as glucuronide conjugates and unchanged drug; biliary/fecal: ~25% as metabolites.
Category C
Category C
Progestin
Progestin